Humanin vs NAD+
A side-by-side research comparison of Humanin and NAD+ across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Humanin | NAD+ |
|---|---|---|
| Full name | Humanin (HN) Mitochondrial-Derived Peptide | Nicotinamide Adenine Dinucleotide (NAD+ / NMN / NR) |
| Category | Anti-Aging | Anti-Aging |
| Status | Research compound | Research compound |
| Mechanism | Binds IGFBP-3, BAX, and trimeric receptor (CNTFR/WSX-1/gp130) to activate STAT3. Inhibits mitochondrial apoptosis and provides neuroprotection. | NAD+ serves as cofactor for sirtuins (SIRT1-7), PARPs (DNA repair), and CD38. Declining NAD+ impairs mitochondrial function and epigenetic maintenance. Restoration reactivates longevity pathways. |
| Molecular weight | 2,687 Da | 663.4 Da |
| Half-life | 4-6 hours | 1-4 hours (IV), 4-8h (oral precursors) |
| Bioavailability | Moderate (SubQ) | 100% (IV), variable (oral 5-30%) |
| Typical dose | 1-5 mg | 250-500mg IV or 500-1000mg NMN oral |
| Frequency | 3-5x per week | Weekly (IV) or Daily (oral) |
| Route | Subcutaneous | IV infusion or Oral (precursors) |
Humanin reported benefits
- Neuroprotection against amyloid-beta
- Anti-apoptotic
- Improved insulin sensitivity
- Cardioprotection
- Cellular stress resistance
NAD+ reported benefits
- Restored cellular energy
- Enhanced DNA repair
- Sirtuin activation
- Improved mitochondrial function
- Cognitive clarity
- Anti-aging
Related comparisons
Research and educational reference only. Not medical advice.